2 active not recruiting, 2 completed, 2 withdrawn, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Metastatic Adrenal Gland Pheochromocytoma: new trials by email Literature Review of Metastatic Adrenal Gland Pheochromocytoma trials Research Report on Metastatic Adrenal Gland Pheochromocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging - Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 46 | 2021-03-17 | 2026-09-10 |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Lutetium Lu 177 Dotatate - Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-13 | 2020-09-07 | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-31 | 2024-02-20 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration - Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2015-02-17 | 2025-07-31 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2011-05-01 | 2017-09-21 |
Pheochromocytoma (7) · Paraganglioma (5) · Adrenal Cortex Neoplasms (2) · Carcinoma, Medullary (2) · Paraganglioma, Extra-Adrenal (2) · Carcinoid Tumor (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Small Cell (1) · Glucagonoma (1) · Insulinoma (1) · Multiple Endocrine Neoplasia Type 1 (1) · Multiple Endocrine Neoplasia Type 2a (1) · Multiple Endocrine Neoplasia Type 2b (1) · Neoplasm Metastasis (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neuroendocrine Tumors (6) · Adenocarcinoma (3) · Carcinoma (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Adrenal Cortex Diseases (2) · Adrenal Gland Diseases (2) · Adrenal Gland Neoplasms (2)
Temozolomide (2) · Capecitabine (1) · Contrast Media (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · cabozantinib (1) · lenvatinib (1) · lutetium Lu 177 dotatate (1) · olaparib (1) · pazopanib (1) · pembrolizumab (1) · veliparib (1)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2) · Mayo Clinic (1) · Vanderbilt-Ingram Cancer Center (1)
United States (6) · Hong Kong (1) · Singapore (1)
Camilo Jimenez (2) · Ashish Chintakuntlawar (1) · Aung Naing (1) · Jaydira Del Rivero (1) · Jordan Berlin, M.D. (1) · Keith Bible (1)
PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35618285, PMID 35999229, PMID 37568622, PMID 38608693, PMID 40212844, PMID 41143139, PMID 42342409
P30CA015083 (2), N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), U10CA180821 (1)